Just Answers - Finance

The concept of buying and selling charged off receivables dates back decades. Until recently it has been so much in th

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

e shadow of conventional contingency placement system as to be virtually invisible. Ask yourself, have you ever heard

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

f this business? So now suddenly there is an open market for bad debt,complete with a variety of sellers, several tier

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

of buyers and even a layer of brokers and middleman.

The selling of debt is measured in paper with a face value of t

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ens of billions of dollars, on a yearly basis. Most of it sells at huge discounts , typically pennies on the dollar.

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

It is reshaping the face of the credit and collections industry. As the debt buying and selling growth rate of the pas

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

few years accelerates, the trend continues to develop into a force in which the majority of debt is sold as opposed t

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

o being outsourced to collection agencies.

The concept of the market is simplistic itself. When credit granters no lo

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ger want to own their charged off debt, they sell the rights to the debt to another party (you) which will then hire

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

it out for collection to an agency. The age of the paper ranges from early development of delinquency to being several

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

years delinquent, which is all good in their own class. Credit card issuers have been the leaders in the bad debt mark

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

et.

Even more diverse are the buyers of the charged off accounts. Some are the traditional collection agencies, tryin

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

to diversify their operations by adding some debt they own to their contingency work for clients. Some are collection

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

attorneys. And then there is, the private investor which will be brought into this industry through a very special bus

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

iness opportunity. Over a quarter of the buyers are private investors with no experience in collections. Most of the i

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

vestors negotiate with collection agencies to actually work and collect the accounts purchased. This is most profitabl

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

for both parties, since the investor lacks the experience in collections, while the agency possesses the resources ne

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

eded to recover the account receivables.

New investment opportunities exist out there that teach you how to become a

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

private investor, find debt for pennies on the dollar, negotiate and hire a collection agency, all while having other

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

do 97% of the work for you.

http://www.moneyoffofdebt.com

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

There are no hard and fast rules on how to blog. Having said that, bloggers will likely increase their exposure by following some simple blog guidelines.

Tired of seeing clicks that are paying your $0.10? There is something you can do about it.

Tags

Links

Just Answers - Make Money Off Of The Debt Of Others

Related Articles: